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 Proteinase-activated receptors (PARs), a group of G protein-coupled receptors, are 
activated by the cleavage of their N-terminal domain by serine proteinases [1, 2]. The 
proteolytic cleavage of the N-terminal region of PARs unmasks a new N-terminal sequence 
that acts as a tethered ligand that binds and activates the receptor itself [1]. The PAR2 subtype 
is highly expressed in the skin, is activated by trypsin and mast cell tryptase, and can be 
activated without the need for proteolysis by synthetic PAR2 agonists, such as SLIGRL-NH2 
[1, 3]. Tryptase and PAR2 are up-regulated on sensory nerves in the skin from atopic 
dermatitis patients [2]. Indeed, intradermal injections of SLIGRL-NH2 evoke dose-dependent 
scratching in mice [4]. In addition, PAR2 agonists induce the release of neuropeptide, such as 
substance P, from primary afferent neuron [5]. Pretreatment of mice with a histamine H1 
receptor antagonist, pyrilamine, has no effect on PAR2-mediated scratching [4]. These results 
indicate that PAR2 signaling induces itching independently of histamine H1 receptor signaling. 
 Olopatadine hydrochloride ((Z)-11-(3-dimethylaminopropylidene)-6,11-dihydrodinenz 
[b,e]oxepin-2-acetic acid monohydrochloride) is a second-generation antihistamine. 
Olopatadine inhibits ear swelling and cytokine production in a murine chronic contact 
hypersensitivity model, while other antihistamines do not suppress them, suggesting that 
olopatadine exerts additional biological effects besides its blockade of histamine H1 receptor 
[6]. In this study, we examined the effect of olopatadine on PAR2 agonist-induced scratching 
behavior in mice. 
 Scratching behavior with a PAR2 agonist was induced on the shaved neck of 6-8 weeks old 
C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME, USA) by subcutaneously injecting 50 
l of a PAR2 agonist 2f-LIGRL-amide (1 mg/ml in phosphate-buffered saline (PBS); 
Calbiochem, Dermstadt, Germany). Injected mice were individually transferred to cages for 
observation from one hour before subcutaneous injection for acclimatization. Room 
temperature was maintained at 22 to 25°C. Scratching behavior was counted as once when a 
hind leg of the animal touched the shaved area and returned to the ground, as previously 
described [4]. The number of scratching behavior was counted from -10 to 40 minutes 
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defining the time of administering the PAR2 agonist as 0 minutes. The total number of 
scratching was the sum of scratching behavior from 0 to 30 minutes. Subcutaneous 
administration of PBS alone induced no scratching behavior in mice (data not shown). The 
skin sections stained with hematoxylin and eosin which was excised from shaved neck after 
30 minutes of treatment with the PAR2 agonist or PBS were used for histological evaluation. 
We also examined expression levels of preprotachykinin A mRNA, the precursor for 
substance P, in the skin using quantitative real time polymerase chain reaction according to 
the manufacturer’s instructions (Applied Biosystems, Forester City, CA, USA). In addition, 
immunohistochemical analysis of substance P using anti-substance P monoclonal antibodies 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) was done. Plasma levels of substance P 
were measured by a specific ELISA (R&D Systems, Mineapolis, MN, USA). 
 Olopatadine was orally given once at 1, 3, 10, or 30 mg/kg through a tube together with 1 
ml of PBS 30 minutes before subcutaneous injection of the PAR2 agonist. Pyrilamine 
(Sigma-Aldrich, St. Louis, MO, USA), a histamine H1 receptor antagonist, was used to 
confirm that the PAR2 agonist-induced scratching behavior is not mediated by histamine H1 
receptor. Pyrilamine (10 mg/kg) was subcutaneously injected into the hip of mice 30 minutes 
before the administration of the PAR2 agonist. Furthermore, we examined the effect of 
olopatadine on the itch evoked by 150 μg of substance P (Peptide Institute, Osaka) treatment 
as the method for the PAR2 agonist treatment. Mice orally given only PBS served as a control 
group. 
 The PAR2 agonist induced scratching behavior just after the administration and its effect 
continued until 30 minutes after the administration (Figure 1A). The number of scratching 
behavior reached the maximum 5 minutes after the PAR2 agonist administration at all groups 
and then decreased with time. Pretreatment with olopatadine significantly decreased the 
number of scratching behavior in mice treated at all doses compared with that in control mice. 
In addition, inhibition of the number of scratching behavior was almost dependent on the dose 
of olopatadine. According to the skin hematoxylin and eosin staining pictures, the PAR2 
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agonist treatment induced substantial cutaneous edema compared with PBS treatment, which 
was inhibited by olopatadine administration (Figure 1C). By contrast, the number of 
scratching behavior in the pyrilamine-pretreated group was comparable to that in the control 
group, suggesting that the inhibitory effect of olopatadine on the PAR2 agonist-induced 
scratching behavior is not mediated by histamine H1 receptor. Similar results were obtained 
for the total number of scratching that was the sum of scratching behavior from 0 to 30 
minutes (Figure 1B).  
 Plasma levels of substance P increased by the PAR2 agonist treatment (Figure 2B), though 
there were no significant differences in the skin preprotachykinin A mRNA expression levels 
(Figure 2A). However, secreted substance P could not be detected in the PAR2 agonist- or 
PBS-treated skin. Although this discrepancy is unclear, it might be due to short half-life of 
substance P and/or high solubility of substance P in organic solvent, such as formaldehyde, 
and water which were used for the fixation and staining of skin samples [7]. Olopatadine 
preadministration inhibited elevation of plasma substance P levels induced by the PAR2 
treatment (Figure 2B). Furthermore, substance P treatment induced scratching behavior, 
which was inhibited by olopatadine pretreatment (Figure 2C). 
 Histamine is the important mediator of itching in allergic skin diseases [2]. However, it is 
well recognized in the routine clinical setting that itching of atopic dermatitis, nasal 
congestion in allergic rhinitis, and bronchial asthma do not always respond to H1 
antihistamines. Our finding that H1 antihistamine, pyrilamine did not inhibit scratching 
induced by the PAR2 agonist suggests that H1 antihistamine-resistant itching is mediated in 
part by PAR2 signaling. Furthermore, the significant inhibitory effect on PAR2-induced itching 
by olopatadine suggests that olopatadine may be effective for H1 antihistamine-resistant 
itching. 
 Many studies have shown that olopatadine has various pharmacological and biological 
activities besides its histamine H1 receptor antagonistic activity [6]. In particular, olopatadine 
suppresses release of neuropeptides, including substance P and calcitonin gene-related peptide, 
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from afferent neurons. Increased expression of substance P in the spinal dorsal horn following 
repeated hapten application is inhibited by olopatadine [8]. Olopatadine also attenuates the 
enhancement of capsaicin-induced substance P release by bradykinin from cultured dorsal 
root ganglion neurons [9]. Moreover, olopatadine decreases plasma levels of substance P in 
patients with atopic dermatitis, while cetiridine and fexofenadine do not decrease them [10]. 
In this study, olopatadine inhibited the PAR2 agonist-induced substance P secretion. 
Furthermore, olopatadine decreased substance P-induced scratching behavior. Collectively, 
the inhibitory effect on PAR2-induced itching by olopatadine may be related to the inhibition 
of substance P release and substance P-induced itching by olopatadine, which is downstream 
of PAR2 signaling. 
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Figure 1. The time course (A) and total number (B) of the PAR2 agonist-induced scratching 
behavior in either olopatadine- or pyrilamine-pretreated group. Thirty minutes before the 
PAR2 agonist administration, olopatadine was orally administered once at each dose and 
pyrilamine was subcutaneously injected into the hip of mice. The time of administering the 
PAR2 agonist was defined as 0 minutes. Mice orally given only PBS served as a control group. 
Representative histological sections stained with hematoxylin and eosin are shown (C). The 
skin sections were excised from shaved neck after 30 minutes of treatment with the PAR2 
agonist or PBS. Each group consisted of 6 mice. Values are expressed as mean ± SD. Original 
magnifications, x100. 
 
Figure 2. Levels of preprotachykinin A (PPT-A) mRNA expression in the skin (A) and 
substance P in the plasma samples (B) from the PAR2 agonist- or PBS-treated mice. The skin 
and plasma samples were obtained after 30 minutes of treatment with the PAR2 agonist or 
PBS. Effect of olopatadine on total number of scratching behavior induced by substance P. 
Thirty minutes before substance P administration, olopatadine was orally administrated once 
at each dose. Total number of scratching behavior was counted from 0 to 30 minutes defining 
the time of administering substance P as 0 minutes. Mice orally given only PBS served as a 
control group. Each group consisted of 6 mice. Values are expressed as mean ± SD. 
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